The acquisition of Systagenix enhances KCI’s position as a leading provider of transformational healing solutions with a diverse product portfolio dedicated to advancing the practice of medicine and improving the lives of patients around the world.
Senior associate Niels Geuze: ‘We have a long and excellent relationship with One Equity Partners. Working with them on the KCI transaction was again a very enjoyable and interesting experience. In addition to advising on the Dutch law aspects of the sale, we coordinated a pre-closing restructuring of Systagenix involving some fifteen jurisdictions. This matches well with De Brauw’s strategy: to be the trusted adviser of our clients, both nationally and internationally, in any jurisdiction, with the assistance of local counsel as needed.’
René Clumpkens (lead partner)